Streetbeat News

Regulatory

MBRX

Moleculin Biotech has begun dosing subjects in the Phase 2 portion of its clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of Acute Myeloid Leukemia (AML). The Phase 1B portion of the study demonstrated a preliminary CR/CRi rate of 33%. Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for the treatment of AML.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:41 pm

ETHE

ETHUSD

Grayscale Investments, the world's largest crypto asset manager, has announced that NYSE Arca has filed Form 19b-4 with the SEC to convert Grayscale Ethereum Trust (ETHE) to a spot Ethereum ETF. This follows the SEC's clearance of the first Ethereum futures ETFs. ETHE, launched in March 2019, is the largest Ether investment vehicle in the world, with assets under management of nearly $5b, representing 2.5% of all Ether in circulation.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:37 pm

IPX

IperionX Limited (NASDAQ:IPX) has partnered with GKN Aerospace to deliver titanium plate test components manufactured with IperionX's advanced titanium technologies. The collaboration builds on the successful testing and validation of IperionX's 100% recycled titanium powder made from GKN scrap titanium feedstocks. The partnership may also extend to projects linked to the U.S. Department of Defense. IperionX aims to re-shore titanium mineral and metal production in the U.S., reducing reliance on primary titanium imports.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:36 pm

MIRM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has announced positive data from the Phase 3 RESTORE study evaluating Chenodal tablets in patients with cerebrotendinous xanthomatosis (CTX). The study met its primary endpoint with a significant reduction in bile alcohols. The company plans to submit these data to the FDA and file a new drug application in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:33 pm

EAST

Eastside Distilling has completed a debt-for-equity exchange, converting $6.51M of outstanding debt into equity at $3.05/share. This has significantly reduced the company's debt and improved its near-term cash flow. The transaction has also extended the maturities of a significant portion of the remaining debt to March 2025 and will enable the company to regain compliance with the NASDAQ's Shareholders Equity requirement.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:23 pm

SPY

In a recent CNBC interview, Bill Ackman, a well-known hedge fund manager, stated that he believes the economy is beginning to slow down and that the Federal Reserve is likely done with its rate hikes.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:22 pm

HZNP

Horizon Therapeutics (NASDAQ:HZNP) has announced that new analyses of its drug UPLIZNA will be presented at the 39th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2023. UPLIZNA is the first and only targeted CD19+ B-cell-depleting therapy approved by the FDA, the European Commission, and the Brazilian Health Regulatory Agency for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) in adults.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:14 pm

ICCM

An independent study conducted in Spain has validated the safety and effectiveness of IceCure Medical Ltd.'s (NASDAQ:ICCM) ProSense Cryoablation system as an outpatient procedure for breast cancer, with a success rate of 96.8%. The study involved women who declined standard surgery and used ProSense for cryoablation treatment. The study concluded that cryoablation could be an alternative treatment to surgery for breast cancer in patients who reject surgery.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:09 pm

IMMX

Immix Biopharma has announced clinical data for NXC-201 at the IMS 20th Annual Meeting, showing a 95% overall response rate in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. The company plans to submit a BLA for FDA approval in multiple myeloma once 100 patients are treated with NXC-201.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 12:07 pm

AMD

INTC

NVDA

The European Union is scrutinizing the AI chip market, focusing on potential anticompetitive behaviors, with Nvidia Corp (NVDA) being a primary focus due to its dominant position. The European Commission is investigating the sector, particularly graphics processing units (GPUs), to determine if intervention is needed. French regulators are also probing Nvidia's role in the market. Concerns revolve around the company's pricing policies and the ongoing chip shortage. Nvidia's H100 processing units have helped it secure over 80% of the market share, outpacing competitors like Intel Corp (INTC) and Advanced Micro Devices Inc (AMD).

Portfolio Pulse from Anusuya Lahiri

October 02, 2023 | 12:03 pm